Researchers have found that a treatment called RYTELO® (imetelstat) may be effective for people with lower-risk myelodysplastic syndromes (LR-MDS), a type of blood cancer that can lead to severe anemia and frequent blood transfusions. The study, conducted at the Moffitt Cancer Center, reported that 37.5% of patients who were heavily dependent on transfusions became independent from them for at least eight weeks after receiving imetelstat. This finding is particularly relevant for individuals who have not responded to other therapies.

For those looking to age well and maintain their health, this new treatment option could significantly improve quality of life. Many people with LR-MDS experience debilitating fatigue and other symptoms due to their condition and the need for frequent blood transfusions. If imetelstat continues to show positive results, it could help these individuals regain energy and reduce their reliance on transfusions, ultimately enhancing their overall well-being.

The evidence comes from a real-world study involving 40 patients, which is a promising step forward but still early-stage. While the results align with previous findings from a larger Phase 3 clinical trial, more research is needed to confirm the long-term benefits and safety of imetelstat in diverse patient populations. The study’s safety profile was generally consistent with what has been seen in trials, but some patients experienced significant side effects, such as low blood cell counts.

If you’re interested in this treatment, it’s essential to discuss it with your healthcare provider, especially if you or someone you know is dealing with LR-MDS. They can provide personalized advice based on individual health needs and treatment history.

Source: globenewswire.com